The Marie Curie IAPP project “Industria-Academia exchange to further FXR-based therapeutic intervention and non-invasive diagnosis in Inflammatory Bowel Disease”, in short “FXR-IBD” is starting on January 1, 2014. Funded by the European Commission (total value of the project M€ 1.5), the training project will bring together knowledge both from industry and academia, in the context of an innovative research project on novel diagnostic and therapeutic approaches for IBD and provide further education and training to a large group of researchers. The FXR-IBD consortium is coordinated by Dr. Saskia van Mil from the UMC Utrecht and consists of UMC Utrecht (Netherlands), TES Pharma (Italy) and Enterome Bioscience (France).